Advancing structural biology research with the GenNext AutoFox® Protein Footprinting System and Agilent 6560 Ion Mobility Quadrupole Time-of-Flight (IM-QTOF) LC/MS system

GenNext Technologies and Agilent have announced a pioneering collaboration that promises to transform structural biology research for biopharmaceutical companies. The integration of GenNext's AutoFox Protein Footprinting System with Agilent's 6560 Ion Mobility Quadrupole Time-of-Flight (IM-QTOF) LC/MS System presents an unparalleled approach to detailed protein structure analysis and biomolecular interaction studies. This fusion of technology platforms enables biopharmaceutical researchers to achieve deeper insights with greater ease, facilitating high-value decisions faster than ever before.

Cutting-Edge Technology Synergy

The advanced workflow starts with Hydroxyl Radical Protein Footprinting (HRPF) by the GenNext AutoFox System followed by detection and quantification on the Agilent IM-QTOF System and then finishes with data analysis using GenNext’s FoxWare® and Agilent’s MassHunter IM-MS software.

GenNext’s AutoFox Protein Footprinting System with FoxWare Software is trusted for delivering high-resolution protein footprinting data, enabling researchers to gain profound insights into protein structures and conformational changes. This system is highly regarded for its precision, reproducibility, and efficiency in mapping protein-ligand interactions, therapeutic-target interactions, and protein conformations in their native environments.

Agilent's 6560 IM-QTOF LC/MS system, known for its advanced ion mobility separation coupled with high-resolution mass spectrometry, allows for the precise analysis of complex biological samples. Its capability to separate ions based on their shape and charge provides an added dimension of structural information crucial for comprehensive protein analysis.

"We are thrilled about the possibilities the Agilent collaboration opens up for structural biology research," said Scot Weinberger, CEO of GenNext Technologies. "The integration of our two powerful technologies offers researchers a state-of-the-art toolset for advancing their understanding of protein structures and interactions."

"Agilent is committed to pushing the boundaries of scientific discovery," added Jennifer Gushue, Associate Vice President of LC/MS Marketing at Agilent. "Our IM-QTOF system, combined with GenNext's innovative protein footprinting technology, will provide researchers with the critical insights needed to drive the next generation of biopharmaceutical advancements."

Ion Mobility and AutoFox Enhance Protein Footprinting

Historically, protein footprinting faced complications from co-eluting peptidoforms that resulted in chimeric tandem mass spectrometry measurements. The combination of ion mobility-tandem mass spectrometry with AutoFox protein footprinting resolves this issue, as ion mobility deconvolves complex tandem mass spectrometry measurements, providing confident amino acid-level structural resolution. These improved structural insights aid in the design of more effective therapeutics, expediting the development pipeline and enhancing drug efficacy.

This technology combination facilitates the collection of more comprehensive and detailed data, deepening the understanding of protein functions and mechanisms through enhanced protein structural resolution. Data generated from the workflow collaboration will be showcased at the CASSS MS meeting during the Wednesday’s lunch seminar on "AutoFox® Protein Footprinting System Provides Amino Acid Resolution for Protein HOS Studies," presented by Dr. Emily Chea of GenNext Technologies.

About GenNext Technologies

GenNext Technologies, Inc., provides instrumentation, software, and services for research into biopharmaceutical structure, interactions, folding, aggregation, formulation, and delivery. Our powerful, automated, and cost-effective platform enables researchers to conduct reproducible Higher Order Structure experiments quickly, easily, and safely. We help our customers accelerate biopharmaceutical development, while improving therapeutic efficacy and safety. Ultimately, our mission is to enable structural biology researchers to discover and develop drug therapies that improve human health.